Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00445146 · ClinicalTrials.gov registry record · Phase 2
Safety of EVG+RTV Administered With Other Antiretroviral Agents for the Treatment of HIV-1 Infection
A Phase 2 study, sponsored by Gilead Sciences.
- Completed
- Registry status
- Phase 2
- Development phase
- 192
- Enrollment target
NCT00445146 is a Phase 2 study that has completed, run by Gilead Sciences. The registered enrollment target is 192 participants.
The verdict
NCT00445146, a Phase 2 study, has completed, sponsored by Gilead Sciences.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 192 participants
- Enrollment target
Study Summary
The main objective of this study is to observe the long-term safety of elvitegravir (EVG) boosted with ritonavir (RTV) in combination with other antiretroviral (ARV) agents in participants who have completed a prior EVG+RTV treatment study.
Interventions
- DRUG RTV
- DRUG ARV regimen
- DRUG EVG
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 192 participants |
| Start Date | 2007-02 |
| Est. Completion | 2015-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00445146
The ClinicalTrials.gov registry entry for NCT00445146 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 192 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Gilead Sciences, which has 504 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which RTV is the first listed.
NCT00445146 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00445146 about?
NCT00445146 is a clinical study titled "Safety of EVG+RTV Administered With Other Antiretroviral Agents for the Treatment of HIV-1 Infection". The main objective of this study is to observe the long-term safety of elvitegravir (EVG) boosted with ritonavir (RTV) in combination with other antiretroviral (ARV) agents in participants who have completed a prior EVG+RTV treatment study.
What is the current status of trial NCT00445146?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 192 participants. The study started on 2007-02. Estimated completion is 2015-03.
What interventions are being tested in trial NCT00445146?
The interventions under investigation include: RTV (DRUG), ARV regimen (DRUG), EVG (DRUG).
Who is sponsoring clinical trial NCT00445146?
This trial is sponsored by Gilead Sciences, which has 504 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.